News Archive

At North Dakota State this semester, I took a course titled “Economics of Entrepreneurship”. It was a deep dive into economic theory with a focus on entrepreneurship. Throughout the course, it surprised me how often I was able to connect anecdotes from sports to the various theories we were learning about. When it came time to write a research paper for the semester, I was able to take an in-depth look at the relation between economic theory and MLB front offices, especially since Billy Beane. Following a few excerpts from what I wrote, I’ll take a look at the Levine-Falvey administration in this context.

ROCKVILLE, Md., May 15, 2020—Supported by a special appropriation by the Council, the Montgomery County Economic Development Corporation (MCEDC) has awarded 25 local businesses with funds totaling $200,000 for the manufacture of Covid-19-related personal protective equipment (PPE).

Councilmember Hans Riemer initiated the appropriation and partnered with MCEDC to create the Local Production Fund. MCEDC administers the fund and matched the Council’s $100,000 appropriation with $100,000 from their budget.

Image: http://councilmemberriemer.com

TOPLINE Public vaccine company Novavax announced today that it will receive up to $388 million from the Coalition for Epidemic Preparedness (CEPI) to continue development and manufacturing of its COVID-19 vaccine candidate.

Silicon Valley Super Angel Angel Investor, Dr. Faz Bashi, M.D., joins BioTalk from the West Coast to discuss the Venture Capital, partnerships and staying connected in the age of COVID-19

Dr. Faz Bashi, M.D., has a background in Immunology and Virology from UCSF. Faz is an active member of the LSA screening committee for Biotechnology and Pharmaceuticals as well as the Medical Device + Digital Health Screening Committee. He is the Emeritus Board member of the Angel Capital Association (ACA), and Chair of the ACA’s Life Sciences Syndication Group, and Affiliate Partner at Boston Millennia Partners and Lead Venture Investor at Portfolia’s FemTech Fund

Early reports of the COVID-19 pandemic, created an initial widespread impression that children were not severely affected by the virus. This understanding was framed by data from China which showed that less than 1 percent of cases occurred in children younger than 10. However, this consensus is now being challenged by new reports, including one in the New England Journal of Medicine from Wuhan Children’s Hospital, which found a pediatric infection rate of more than 12 percent.

About 48 hours after a Seattle woman received the first dose of an experimental vaccine against SARS-CoV-2, scientists in China—not to be outdone—announced that they had regulatory approval to launch an ambitious vaccine trial as well. The Seattle volunteer received a messenger RNA vaccine that Moderna Therapeutics developed to prevent infection with the pandemic virus. The Chinese scientists, representing CanSino Biologics, described their plans to evaluate a recombinant vaccine.

Lauren Gardner, an associate engineering professor at Johns Hopkins University, was sitting in a school coffee shop with two graduate students in January, chatting about their work on measles, Dengue fever and the Zika virus, when conversation turned to an emerging coronavirus in China.

BALTIMORE, May 7, 2020 /PRNewswire/ — Pumas-AI, a University of Maryland, Baltimore (UMB) startup company, has been granted worldwide, exclusive rights to Lyv, a cutting-edge clinical decision support system designed to help health care professionals personalize treatment trajectories for patients in real-time.

The Lyv platform leverages clinical research and Electronic Health Record (EHR) data from millions of patients to derive algorithms that can personalize health care delivery. Lyv will have modules for anti-infectives, anti-epileptics, anti-coagulants, and anti-cancer that can be used in a hospital setting, and can also incorporate algorithms during new drug development. By personalizing treatment, Lyv can help improve therapeutic success rates and minimize dosing errors.